Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
June 25 2024 - 11:45AM
UK Regulatory
Higher cantonal composition authority approved the amendments to
the terms of the 2024 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – June 25, 2024
Idorsia Ltd (SIX: IDIA) today announced that the hearing by the
higher cantonal composition authority (obere kantonale
Nachlassbehörde) (the Court) in relation to its outstanding
convertible bonds originally maturing on July 17, 2024 (ISIN:
CH0426820350) (the Bonds), was held today and that the Court
approved the amendments of the Bond terms decided at the bondholder
meeting held on May 6, 2024.
Idorsia will announce when it has received the written statement
of the grounds. The amended terms will become effective, if no
appeal is filed against the court decision, within 30 days from the
official publication of the written statement of the grounds.
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see
more opportunities and we want to help more patients. In order to
achieve this, we will develop Idorsia into a leading
biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 25-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North
America – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 750 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate
Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123
Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Idorsia (LSE:0RQE)
Historical Stock Chart
From Oct 2024 to Nov 2024
Idorsia (LSE:0RQE)
Historical Stock Chart
From Nov 2023 to Nov 2024
